A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 594 KB, PDF-dokument

  • Rolf Markus Szeimies
  • Thomas Dirschka
  • Maria Concetta Fargnoli
  • Yolanda Gilaberte
  • Hædersdal, Merete
  • Rajeev Chavda
  • Piergiacomo Calzavara-Pinton
Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population.
TidsskriftDermatology and Therapy
Udgave nummer7
Sider (fra-til)1409-1421
Antal sider13
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Sponsorship for this study and Rapid Service Fee were funded by Galderma SA.

Funding Information:
Medical writing was provided by Dr. Gopika Nithianandarajah from Ogilvy Health UK. Support for this assistance was funded by Galderma SA.

Publisher Copyright:
© 2023, The Author(s).

ID: 365663369